Ebert E C, Wright S H, Lipshutz W H, Hauptman S P
Clin Immunol Immunopathol. 1984 Nov;33(2):232-44. doi: 10.1016/0090-1229(84)90078-3.
Inflammatory bowel disease (IBD) may be an immunologically mediated disorder in which T cells are unable to respond appropriately to cell surface-associated antigens. To test this possibility, 37 patients with IBD, 24 with Crohn's disease and 13 with ulcerative colitis who were not being treated with immunosuppressive therapy were studied. The ability of T cells to proliferate in response to autologous or allogeneic cells, i.e., the autologous or allogeneic mixed-lymphocyte reaction (MLR) was tested. The autologous MLR was depressed using patient cells compared to control cells, regardless of disease type or activity (1564 +/- 223 cpm versus 3300 +/- 381 cpm, P less than 0.05) while the allogeneic MLR was depressed in patients with active disease only (29,833 +/- 2871 cpm versus 46,799 +/- 3340 cpm, P less than 0.01). The ability of T cells to recognize and lyse allogeneic cells, allogeneic cell-mediated lympholysis (CML), was also low in patients with active disease (24 +/- 4% versus 37 +/- 3%, P less than 0.05). Since T-cell proliferation and cytotoxicity depend upon adequate production of and response to a T-cell growth factor, interleukin 2 (IL-2), IL-2 production and responsiveness in IBD were studied. IL-2 production by patient T cells in response to phytohemagglutinin was only 39% of control values, P less than 0.05. The response to IL-2 was measured by the increase in T-cell proliferation in the autologous MLR in medium alone or medium supplemented with IL-2. Control T-cell proliferation rose from 3300 +/- 381 cpm to 10,761 +/- 428 cpm with exogenous IL-2 (P less than 0.001). Patient T-cell proliferation rose from 1564 +/- 223 cpm to 6817 +/- 771 cpm with IL-2 (P less than 0.001) but did not reach the level of the IL-2-supplemented control autologous MLR (P less than 0.05). In addition, the percentage of activated patient T cells having Tac antigen (IL-2 receptor) was depressed (P less than 0.05). These findings did not vary with disease type or activity. It is concluded from these data that peripheral blood T lymphocytes from patients with IBD have a diminished response to cell surface antigens which is associated with a decrease in IL-2 production and receptor generation. These defects may be responsible for the depressed T-cell proliferation and cytotoxicity that accompany IBD.
炎症性肠病(IBD)可能是一种免疫介导的疾病,其中T细胞无法对细胞表面相关抗原做出适当反应。为了验证这种可能性,对37例未接受免疫抑制治疗的IBD患者进行了研究,其中24例患有克罗恩病,13例患有溃疡性结肠炎。检测了T细胞对自体或异体淋巴细胞的增殖能力,即自体或异体混合淋巴细胞反应(MLR)。与对照细胞相比,使用患者细胞时自体MLR受到抑制,无论疾病类型或活动状态如何(1564±223 cpm对3300±381 cpm,P<0.05),而异体MLR仅在患有活动性疾病的患者中受到抑制(29,833±2871 cpm对46,799±3340 cpm,P<0.01)。在患有活动性疾病的患者中,T细胞识别和裂解异体淋巴细胞的能力,即异体细胞介导的淋巴细胞溶解(CML)也较低(24±4%对37±3%,P<0.05)。由于T细胞增殖和细胞毒性取决于T细胞生长因子白细胞介素2(IL-2)的充分产生和反应,因此对IBD患者的IL-2产生和反应性进行了研究。患者T细胞对植物血凝素的IL-2产生仅为对照值的39%,P<0.05。通过单独培养基或添加IL-2的培养基中自体MLR中T细胞增殖的增加来测量对IL-2的反应。外源性IL-2使对照T细胞增殖从3300±381 cpm升至10,761±428 cpm(P<0.001)。IL-2使患者T细胞增殖从1564±223 cpm升至6817±771 cpm(P<0.001),但未达到添加IL-2的对照自体MLR水平(P<0.05)。此外,具有Tac抗原(IL-2受体)的活化患者T细胞百分比降低(P<0.05)。这些发现不因疾病类型或活动状态而异。从这些数据得出结论,IBD患者外周血T淋巴细胞对细胞表面抗原的反应减弱,这与IL-2产生和受体生成减少有关。这些缺陷可能是IBD伴随的T细胞增殖和细胞毒性降低的原因。